ArticleAging2019
Epigenetic mortality predictors and incidence of breast cancer.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Progress in epigenetic research of breast cancer: a bibliometric analysis since the 2000s.Frontiers in oncology · 2025Pooled it
- Epigenetic Ageing and Breast Cancer Risk: A Systematic Review.Cancer medicine · 2024Pooled it
- Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method.Frontiers in endocrinology · 2023Pooled it
- Methylation-based markers of aging and lifestyle-related factors and risk of breast cancer: a pooled analysis of four prospective studies.Breast cancer research : BCR · 2022Pooled it
- Pooled it
- Associations of breast DNA methylation-based measures of biological ageing with obesity-related breast cancer risk markers.Epigenetics · 2026Article
- Epigenetic-Metabolic interplay in chronic kidney disease mortality: insights from grimage acceleration and transcriptomic profiling.Clinical epigenetics · 2026Article
- Sex-specific nonlinear DNA methylation aging trajectories reveal biomarkers of cancer risk and inflammation.Genome biology · 2026Article
- Analysis of blood-based DNA methylation signatures of aging and disease progression in inflammatory bowel disease.Human genetics · 2025Article
- From ageing clocks to human digital twins in personalising healthcare through biological age analysis.NPJ digital medicine · 2025Article
- Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab.Cardio-oncology (London, England) · 2025Article
- DNA methylation-predicted plasma protein levels and breast cancer risk.Breast cancer research : BCR · 2025Article
- Review
- Associations of Serum Cystatin C, DNAm Cystatin C, Renal Function, and Mortality in U.S. Adults.Life (Basel, Switzerland) · 2024Article
- Article
- Changes in methylation-based aging in women who do and do not develop breast cancer.Journal of the National Cancer Institute · 2023Article
- Accelerated epigenetic aging and decreased natural killer cells based on DNA methylation in patients with untreated major depressive disorder.npj aging · 2023Article
- Inequalities in urban greenness and epigenetic aging: Different associations by race and neighborhood socioeconomic status.Science advances · 2023Article
- Methylation-Based Biological Age and Hypertension Prevalence and Incidence.Hypertension (Dallas, Tex. : 1979) · 2023Article
- DNA methylation accelerated age as captured by epigenetic clocks influences breast cancer risk.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Measures derived using blood DNA methylation are increasingly under investigation as indicators of disease and mortality risk. Three existing epigenetic age measures or "epigenetic clocks" appear associated with breast cancer. Two newly-developed epigenetic mortality predictors may be related to all-cancer incidence, but associations with specific cancers have not been examined in large studies. Using HumanMethylation450 BeadChips to measure blood DNA methylation in 2,773 cancer-free women enrolled in the Sister Study, we calculated two epigenetic mortality predictors: 'GrimAgeAccel' and the 'mortality score' (MS). Using Cox proportional hazard models, neither GrimAgeAccel nor the MS were associated with overall breast cancer incidence (GrimAgeAccel hazard ratio [HR]: 1.06, 95% confidence interval [CI]: 0.98-1.14,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.